StageZero Life Sciences Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
40
- Stock Symbol
-
SZLS
- Investments
-
4
- Share Price
-
$0.03
- (As of Monday Closing)
StageZero Life Sciences General Information
Description
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
Contact Information
Corporate Office
- 70 East Beaver Creek Road
- Suite 30
- Richmond Hill, Ontario L4B 3B2
- Canada
Corporate Office
- 70 East Beaver Creek Road
- Suite 30
- Richmond Hill, Ontario L4B 3B2
- Canada
StageZero Life Sciences Timeline
StageZero Life Sciences Stock Performance
As of 08-Apr-2024, StageZero Life Sciences’s stock price is $0.03. Its current market cap is $3.61M with 124M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.03 | $0.03 | $0.03 - $0.07 | $3.61M | 124M | 85.8K | -$0.12 |
StageZero Life Sciences Financials Summary
As of 30-Sep-2023, StageZero Life Sciences has a trailing 12-month revenue of $2.88M.
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 6,420 | 6,196 | 20,230 | 36,801 |
| Revenue | 2,882 | 3,795 | 5,068 | 4,152 |
| EBITDA | (11,925) | (10,759) | (6,774) | (6,327) |
| Net Income | (12,533) | (11,415) | (7,484) | (6,864) |
| Total Assets | 508 | 701 | 10,646 | 8,508 |
| Total Debt | 1,359 | 1,800 | 1,356 | 3,570 |
StageZero Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
StageZero Life Sciences Comparisons
Industry
Financing
Details
StageZero Life Sciences Competitors (31)
One of StageZero Life Sciences’s 31 competitors is Decipher Urologic Cancers, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Decipher Urologic Cancers | Formerly VC-backed | San Diego, CA | ||||
| Cepheid | Formerly VC-backed | Sunnyvale, CA | ||||
| Novigenix | Venture Capital-Backed | Epalinges, Switzerland | ||||
| Congenica | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Epic Sciences | Venture Capital-Backed | San Diego, CA |
StageZero Life Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
StageZero Life Sciences Patents
StageZero Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20150022117-A1 | Current balancing circuits for light-emitting-diode-based illumination systems | Active | 16-Dec-2011 | ||
| US-9241385-B2 | Current balancing circuits for light-emitting-diode-based illumination systems | Active | 16-Dec-2011 | ||
| US-20140100125-A1 | Methods, kits and compositions for determining severity and survival of heart failure in a subject | Inactive | 30-Jun-2008 | ||
| US-20110223594-A1 | Methods, kits and compositions for determining severity and survival of heart failure in a subject | Inactive | 30-Jun-2008 | ||
| US-20180163276-A1 | Method and apparatus for determining a probability of colorectal cancer in a subject | Active | 10-Apr-2008 | C12Q1/6886 |
StageZero Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
StageZero Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
StageZero Life Sciences Investments & Acquisitions (4)
StageZero Life Sciences’s most recent deal was a Merger/Acquisition with Clinics Operations for . The deal was made on 02-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Clinics Operations | 02-Sep-2021 | Merger/Acquisition | Clinics/Outpatient Services | ||
| Innovative Diagnostic Laboratory | 15-Mar-2016 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Innovative Diagnostic Laboratory | 15-May-2015 | Corporate | Laboratory Services (Healthcare) | ||
| Innovative Diagnostic Laboratory | 02-Jul-2013 | Joint Venture | Laboratory Services (Healthcare) |
StageZero Life Sciences Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Clinics Operations | London, United Kingdom | 2013 |
StageZero Life Sciences FAQs
-
When was StageZero Life Sciences founded?
StageZero Life Sciences was founded in 1997.
-
Where is StageZero Life Sciences headquartered?
StageZero Life Sciences is headquartered in Richmond Hill, Canada.
-
What is the size of StageZero Life Sciences?
StageZero Life Sciences has 40 total employees.
-
What industry is StageZero Life Sciences in?
StageZero Life Sciences’s primary industry is Diagnostic Equipment.
-
Is StageZero Life Sciences a private or public company?
StageZero Life Sciences is a Public company.
-
What is StageZero Life Sciences’s stock symbol?
The ticker symbol for StageZero Life Sciences is SZLS.
-
What is the current stock price of StageZero Life Sciences?
As of 08-Apr-2024 the stock price of StageZero Life Sciences is $0.03.
-
What is the current market cap of StageZero Life Sciences?
The current market capitalization of StageZero Life Sciences is $3.61M.
-
What is StageZero Life Sciences’s current revenue?
The trailing twelve month revenue for StageZero Life Sciences is $2.88M.
-
Who are StageZero Life Sciences’s competitors?
Decipher Urologic Cancers, Cepheid, Novigenix, Congenica, and Epic Sciences are some of the 31 competitors of StageZero Life Sciences.
-
What is StageZero Life Sciences’s annual earnings per share (EPS)?
StageZero Life Sciences’s EPS for 12 months was -$0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
